KMO and Parkinson disease: The alterations of kynurenine metabolites in PD not only provide potential biomarker candidates and novel avenues for investigating PD pathogenesis, but also offer a new therapeutic strategy for PD with the supplement of kynurenic acid or the reduction of quinolinic acid using kynurenine 3-monooxygenase inhibitors [19].